# Crompton Greaves CROM.NS CRG IN

**INDUSTRIALS** 



Belied expectations; downgrade to Reduce

# Receding hopes of a near-term turnaround; downgrade to Reduce

February 9, 2012	
Rating Down from Buy	Reduce
Target price Reduced from 240	INR 130
Closing price February 8, 2012	INR 144
Potential downside	-9.7%

### Action: Margin pressure may continue; Downgrade to Reduce

CRG surprised negatively again in 3Q as subsidiary margins deteriorated further, belying expectations of an improving trend. Management clarified subsequently that the poor margins were not due to inventory liquidation at a discount (in contrast to our initial belief). While we note few positives from the results such as a strong pick-up in power system revenue as well as strong order intake, we are now increasingly concerned over CRG's medium-term margin outlook. Our concerns emanate from the following key observations (in sync with investors who saw this much before us):

- Margins continue to worsen across segments despite a revenue pickup; inspires little confidence in margin recovery when growth stabilises.
- Order inflow in the current environment might continue to deliver subnormal margins due to heightened competitive intensity.
- Management has refrained from giving guidance for the FY13 outlook and has further hinted that the FY12F guidance could be at risk.

### Catalysts: Europe overhang and competition

Profitability in overseas subsidiaries, delayed recovery are key triggers.

### Valuation: Still expensive on our lowered est.; downgrade to Reduce

We believe that CRG is yet to hit the cyclical trough and further downgrade in FY13F earnings is possible. Our revised estimates are still based on the hope of a recovery and we would wait for visible recovery signals. Deteriorating ROE profile and uncertainties prompt us to assign a discount to average sector multiples; we now value the stock at 11x Sep-13F EPS to arrive at our new TP of INR130. Downgrade to Reduce.

31 Mar	FY11		FY12F		FY13F		FY14F
Currency (INR)	Actual	Old	New	Old	New	Old	New
Revenue (mn)	100,051	110,459	111,134	125,990	121,482	147,523	138,522
Reported net profit (mn)	9,268	7,830	4,175	10,302	6,430	12,578	8,794
Normalised net profit (mn)	9,268	7,830	4,175	10,302	6,430	12,578	8,794
Normalised EPS	14.45	12.21	6.51	16.06	10.02	19.61	13.71
Norm. EPS growth (%)	12.4	-15.5	-55.0	31.6	54.0	22.1	36.8
Norm. P/E (x)	9.9	N/A	21.9	N/A	14.2	N/A	10.4
EV/EBITDA (x)	6.9	8.6	10.7	6.7	7.8	5.2	5.8
Price/book (x)	2.8	N/A	2.5	N/A	2.2	N/A	1.9
Dividend yield (%)	1.8	N/A	0.9	N/A	1.4	N/A	1.9
ROE (%)	32.1	21.8	12.1	23.9	16.6	24.0	19.6
Net debt/equity (%)	5.2	3.3	2.4	net cash	net cash	net cash	net cash

Source: Company data, Nomura estimates

Key company data: See page 2 for company data and detailed price/index chart.

### **Anchor themes**

Decades of under-investment, followed by a march towards building sufficient power for the nation, has created significant opportunities, although structural constraints and rising competition suggest the need to be selective.

### Nomura vs consensus

Our earnings estimates are 7%-14% below consensus as we become more cautious on margin recovery.

Research analysts

### **India Capital Goods**

Amar Kedia - NFASL amar.kedia@nomura.com +91 22 4037 4182

Indrajit Yadav - NSFSPL indrajit.yadav@nomura.com +91 22 4037 4992

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

# **Key data on Crompton Greaves**

### Income statement (INRmn)

meonic statement (maxim)					
Year-end 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
Revenue	91,409	100,051	111,134	121,482	138,522
Cost of goods sold	-59,517	-66,916	-80,319	-85,781	-97,073
Gross profit	31,892	33,135	30,816	35,700	41,449
SG&A	-9,542	-9,822	-10,608	-11,456	-12,373
Employee share expense	-11,131	-11,811	-14,174	-15,308	-16,838
Operating profit	11,219	11,502	6,034	8,936	12,237
operaning prom	,	,			,
EBITDA	12,770	13,438	8,559	11,503	15,116
Depreciation	-1,551	-1,936	-2,525	-2,566	-2,878
Amortisation	-1,551	-1,330	-2,020	-2,500	-2,010
EBIT	11 210	11 502	6.024	0.026	12 227
	11,219	11,502	6,034	8,936	12,237
Net interest expense	-428	-352	-474	-572	-572
Associates & JCEs	32	80	80	80	80
Other income	1,100	1,142	670	733	811
Earnings before tax	11,922	12,372	6,310	9,177	12,556
Income tax	-3,650	-3,100	-2,118	-2,729	-3,743
Net profit after tax	8,272	9,272	4,192	6,448	8,814
Minority interests	-26	-4	-17	-18	-20
Other items					
Preferred dividends					
Normalised NPAT	8,247	9,268	4,175	6,430	8,794
Extraordinary items					
Reported NPAT	8,247	9,268	4,175	6,430	8,794
Dividends	-947	-1,645	-822	-1,274	-1,747
Transfer to reserves	7,299	7,623	3,353	5,157	7,047
	-,	.,	-,	-,:	.,
Valuation and ratio analysis					
FD normalised P/E (x)	11.1	9.9	21.9	14.2	10.4
FD normalised P/E at price target (x)	9.2	8.2	18.1	11.8	8.6
Reported P/E (x)	11.1	9.9	21.9	14.2	10.4
Dividend yield (%)	1.0	1.8	0.9	1.4	1.9
Price/cashflow (x)	9.7	17.0	14.5	10.6	9.6
Price/book (x)	3.7	2.8	2.5	2.2	1.9
EV/EBITDA (x)	7.0	6.9	10.7	7.8	5.8
EV/EBIT (x)	8.0	8.0	15.1	10.0	7.1
Gross margin (%)	34.9	33.1	27.7	29.4	29.9
EBITDA margin (%)	14.0	13.4	7.7	9.5	10.9
EBIT margin (%)	12.3	11.5	5.4	7.4	8.8
Net margin (%)	9.0	9.3	3.8	5.3	6.3
Effective tax rate (%)	30.6	25.1	33.6	29.7	29.8
Dividend payout (%)	11.5	17.7	19.7	19.8	19.9
Capex to sales (%)	1.7	7.6	7.7	4.9	4.3
Capex to depreciation (x)	1.0	3.9	3.4	2.3	2.1
ROE (%)	38.0	32.1	12.1	16.6	19.6
ROA (pretax %)	21.4	18.9	8.4	11.2	13.9
Growth (%)					
Revenue	4.6	9.5	11.1	9.3	14.0
EBITDA	28.3	5.2	-36.3	34.4	31.4
EBIT	28.4	2.5	-47.5	48.1	36.9
Normalised EPS	47.3	12.4	-55.0	54.0	36.8
Normalised FDEPS	47.3	12.4	-55.0	54.0	36.8
		14-1	00.0	01.0	
Per share					
Reported EPS (INR)	12.85	14.45	6.51	10.02	13.71
Norm EPS (INR)	12.85	14.45	6.51	10.02	13.71
Fully diluted norm EPS (INR)					13.71
Book value per share (INR)	12.85	14.45	6.51	10.02 64.31	
	39.04	51.05	56.27		75.29
DPS (INR)	1.48	2.56	1.28	1.99	2.72
Source: Company data, Nomura estimates					

### Relative performance chart (one year)



Source: ThomsonReuters, Nomura research

(%)	1M	ЗМ	12M
Absolute (INR)	12.9	-1.6	-46.2
Absolute (USD)	20.9	-1.8	-50.2
Relative to index	0.7	-1.6	-43.1
Market cap (USDmn)	1,859.8		
Estimated free float (%)	54.9		
52-week range (INR)	297/107.1		
3-mth avg daily turnover (USDmn)	6.42		
Major shareholders (%)			
Avantha Holdings	39.9		
Solaris Holding	22.8		
Source: Thomson Reuters,	Nomura research	ı	

FY13F/14F numbers already build in a strong recovery

### Cashflow (INRmn)

Casimon (minimi					
Year-end 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
EBITDA	12,770	13,438	8,559	11,503	15,116
Change in working capital	-125	-4,459	282	357	-1,321
Other operating cashflow	-3,207	-3,588	-2,529	-3,239	-4,255
Cashflow from operations	9,437	5,391	6,311	8,622	9,540
Capital expenditure	-1,526	-7,593	-8,550	-6,000	-6,000
Free cashflow	7,911	-2,202	-2,239	2,622	3,540
Reduction in investments	-3,864	-1,211	3,256	0	0
Net acquisitions					
Reduction in other LT assets					
Addition in other LT liabilities					
Adjustments	1,100	1,142	670	733	811
Cashflow after investing acts	5,148	-2,271	1,687	3,354	4,351
Cash dividends	-947	-1,645	-822	-1,274	-1,747
Equity issue	-2,173	-306	2,446	0	0
Debt issue	0	0	0	0	0
Convertible debt issue					
Others	-996	518	0	0	0
Cashflow from financial acts	-4,116	-1,433	1,623	-1,274	-1,747
Net cashflow	1,032	-3,704	3,310	2,081	2,604
Beginning cash	5,656	6,688	2,984	6,294	8,375
Ending cash	6,688	2,984	6,294	8,375	10,979
Ending net debt	-1,679	1,719	854	-1,226	-3,831
Source: Company data, Nomura estimates					

### Notes

Sufficient free cash flow to fund the current quantum of capex and acquisitions

### Balance sheet (INRmn)

Balance sheet (INRmn)					
As at 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
Cash & equivalents	6,688	2,984	6,294	8,375	10,979
Marketable securities					
Accounts receivable	21,463	25,427	30,448	31,618	36,054
Inventories	10,194	11,893	12,788	13,679	15,484
Other current assets	2,674	5,192	5,307	5,801	6,614
Total current assets	41,018	45,496	54,837	59,473	69,131
LT investments	5,536	6,747	3,492	3,492	3,492
Fixed assets	13,760	19,417	25,442	28,875	31,997
Goodwill					
Other intangible assets					
Other LT assets	0	0	0	0	0
Total assets	60,314	71,660	83,770	91,840	104,620
Short-term debt	•	,	,	•	
Accounts payable	26,567	29,595	35,431	37,900	42,900
Other current liabilities	3,603	4,298	4,774	5,218	5,950
Total current liabilities	30,170	33,892	40,205	43,118	48,851
Long-term debt	5,010	4,703	7,149	7,149	7,149
Convertible debt					
Other LT liabilities	49	160	160	160	160
Total liabilities	35,229	38,756	47,513	50,427	56,159
Minority interest	43	157	157	157	157
Preferred stock	0	0	0	0	0
Common stock	1,283	1,283	1,283	1,283	1,283
Retained earnings	23,760	31,464	34,817	39,973	47,020
Proposed dividends					
Other equity and reserves					
Total shareholders' equity	25,043	32,747	36,100	41,256	48,303
Total equity & liabilities	60,314	71,660	83,770	91,840	104,620
Liquidity (x)					
Current ratio	1.36	1.34	1.36	1.38	1.42
Interest cover	26.2	32.7	12.7	15.6	21.4
Leverage					
Net debt/EBITDA (x)	net cash	0.13	0.10	net cash	net cash
Net debt/equity (%)	net cash	5.2	2.4	net cash	net cash
Assistant and a second a second and a second a second and					
Activity (days)	00.2	05.5	20.2	00.0	00.0
Days receivable	83.9	85.5	92.0	93.2	89.2
Days inventory	64.8	60.2	56.2	56.3	54.8
Days payable	161.3	153.2	148.2	156.0	151.9
Cash cycle	-12.5	-7.4	0.1	-6.5	-7.9
Source: Company data, Nomura estimates					

### Notes

Working capital cycle is lengthening and needs to be tracked

### Margin pressure likely to continue

### 3QFY12 results review

### Above or below consensus?

Crompton Greaves' 3QFY12 results surprised negatively yet again as subsidiary margins deteriorated further, belying expectations of an improving trend. Overall, the results were 36% and 46% below Nomura and consensus estimates, respectively.


In the subsequent analyst meet, management clarified that the poor margins were due to changed product mix, higher raw material cost and one particular project (in the international business) completed during the quarter but that had zero margins. In contrast, we had initially interpreted the fall in margins to be a result of inventory liquidation at a discount.

While we also earlier noted a few positives from the results such as a strong pick-up in power system revenue as well as strong order intake, we are now increasingly concerned over CRG's medium-term margin outlook on the back of continued negative surprises on the same for four quarters in a row.

Our concerns emanate from the following key observations (in sync with investors who saw this much before us):


- Margins continue to worsen across segments despite a revenue pick-up; inspires little confidence in margin recovery when growth stabilises.
- Order inflow in the current environment might continue to deliver sub-normal margins due to heightened competitive intensity.
- Management has refrained from giving guidance for the FY13 outlook and has further hinted that the FY12F guidance could be at risk.

Fig. 1: Sales growth has been under pressure



Source: Company, Nomura estimates

Fig. 2: Forecast margins are still close to peak levels; we see downside risks



Source: Company, Nomura estimates

Fig. 3: CRG 3QFY12 results against estimates

Consolidated results

o o no o na ato a no o anto							
INR Mn	Dec-11	Nomura Est	Consensus Est	Dec-10	Sep-11	Change y-y	Change q-q
Net Sales	30,280	27,378	26,688	23,970	27,055	26%	12%
Operating EBITDA	1,826	2,384	2,459	3,402	2,260	-46%	-19%
EBITDA Margin	6.0%	8.7%	9.2%	14.2%	8.4%		
Reported PAT	771	1,205	1,375	2,328	1,167	-67%	-34%
Recurring EPS (Rs)	1.20	1.88	2.21	3.63	1.82	-67%	-34%

Source: Company data, Bloomberg, Nomura estimates

### What do the results mean?

- The domestic power-systems business returned to solid growth after a gap of almost three years and posted 29.9% y-y growth.
- The domestic industrial-systems business continued to grow in double digits, although it is trending downwards from high teens to early teens now.

- Consumer products' revenue growth remained muted at 5.9% y-y.
- The international business revenue growth was also very strong at 40.6% (possibly also aided by a weakening INR vs. euro during the quarter).
- We notice a sharp liquidation of the stock in trade in the international segment during the quarter this is partly due to the liquidation of unsold custom-built transformers that the company had been carrying since 1QFY12.
- The RM/sales ratio rose sharply in the international business (from ~61% in 1HFY12 to 67.2%).


### **Key numbers**

- CRG reported net income of INR0.77bn against Nomura's estimates of INR1.2bn and consensus estimates of INR1.37bn.
- Sales were strong, 11-13% ahead of Nomura and consensus estimates.
- Consolidated EBITDA margins plunged to 6%, down 240bp y-y mainly on account of a drop in gross margins in the international division.
- We note that the power-systems segment posted strong growth of ~30%y-y compared with a decline of 7% y-y in 2QFY12.

### Key takeaways from management conference call post 3QFY12 results

- Management has refrained from giving guidance for FY13 as well as from confirming
  the guidance given for FY12 on account of changing macro conditions. Management
  had previously given guidance of 10-12% revenue growth and 8-10% EBITDA margins
  at the consolidated level for FY12F during the 1QFY12 call.
- Order inflows in 3QFY12 had been strong at INR34bn with order backlog of INR81.8bn.
   The domestic power-systems business has seen a pick-up in order activities. According to management, the company has received orders for 17 transformers of 756kV rating from Power Grid Corporation of India Limited (PGCIL) in January 2012.

Fig. 4: A sharp pickup in order inflows in Q3FY12 INR bn



Source: Company data

- The project mix accounted for ~500bps margin erosion in the consolidated powersystems segment, while another 300bps erosion due to increased raw material cost. According to management, the margins were also affected by a project worth EUR50mn that fetched zero margin which was completed in the quarter.
- The company has increased capacity of its factories in Indonesia and Brazil to better serve the local markets and get cost advantages.
- The tax benefit from increased R&D spending may not happen in FY12F and the tax rate for the full year is likely to be around 9MFY12 levels of ~34%.

February 9, 2012

• The company has sold the aircraft bought in the previous year at book value. As such, this will have no impact on earnings for FY12.

There has been no increase in loans and advances given to subsidiaries against the previous quarter on account of lower working capital needs. Inventory days decreased from 84 days to 56 days. The debtor days were flat over 1HFY12.

Fig. 5: Detailed results

Consolidated results

INR Mn	Dec-11	Sep-11	Dec-10
Net Sales	30,280	27,055	23,970
Other Income	155	215	120
Total Income	31,347	28,092	24,869
Expenditure			
(Increase)/Decrease - Stock in trade	4,063	(1,847)	423
Consumption of Raw materials	13,961	17,545	11,984
Purchase of traded goods	3,273	2,502	2,490
Staff Cost	3,929	3,574	3,005
Other Expenditure	3,227	3,021	2,667
Interest	112	102	39
Depreciation,amortisation and impairment	627	726	467
Profit before Tax	1,242	1,646	3,017
Provision for Taxation	487	463	703
Net Profit After Tax	755	1,183	2,313
Minority interest and share of associates	16	(17)	15
PAT	771	1,167	2,328
Recurring EPS	1.20	1.82	3.63
Core EBITDA Margin	6.0%	8.4%	14.2%
Tax rate	28.0%	28.1%	23.3%
EBIT Margin			
Domestic power business	10.7%	11.2%	19.8%
International power business	-2.2%	2.3%	8.9%
Consumer products	11.8%	11.3%	14.0%
Domestic Industrial systems	14.6%	15.7%	18.2%
Key cost heads as % of sales			
Raw materials (including trading goods)	70.3%	67.3%	62.1%
Staff cost	13.0%	13.2%	12.5%
Other Expenditure	10.7%	11.2%	11.1%
Core EBITDA	6.0%	8.4%	14.2%
Growth %			
Net sales	26.3%	12.8%	6.7%
Operating Profit	-46.3%	-32.2%	6.2%
PAT	-66.9%	-45.4%	16.4%
Consolidated Segment Revenue			
(a) Power Systems	20,689	17,611	15,452
(b) Consumer Products	5,033	4,801	4,751
(c) Industrial Systems	4,749	4,655	3,809
(d) Others	45	58	57
Total	30,515	27,126	24,069
Consolidated Segment EBIT			
(a) Power Systems	518	934	2,008
(b) Consumer Products	593	543	666
(c) Industrial Systems	494	558	694
(d) Others	8	7	(145)
Total	1,612	2,041	3,223
Consolidated EBIT Margin			
(a) Power Systems	3%	5%	13%
(b) Consumer Products	12%	11%	14%
(c) Industrial Systems	10%	12%	18%

Source: Company data, Nomura research

Fig. 6: 3QFY12 segment results

n INR mn				
Standalone	Dec-11	Sep-11	Dec-10	
Segment Revenue				
(a) Power Systems	7,542	5,988	5,807	
(b) Consumer Products	5,033	4,801	4,751	
(c) Industrial Systems	3,886	3,766	3,497	
(d) Others	19	30	30	
Total	16,481	14,585	14,085	
Less: Intersegment revenue	236	71	99	
Sales/Income from operations	16,245	14,515	13,986	
Standalone Segment Results				
(a) Power Systems	811	672	1,149	
(b) Consumer Products	593	543	666	
(c) Industrial Systems	567	591	637	
(d) Others	2	3	6	
Total	1,972	1,808	2,458	
Standalone Sales Growth %				
(a) Power Systems	29.9%	-7.0%	2.1%	Pick up in power systems after ~3 years
(b) Consumer Products	5.9%	3.6%	30.3%	Consumer products growth remains muted
(c) Industrial Systems	11.1%	9.4%	20.1%	
International division p&L	Dec-11	Sep-11	Dec-10	
Net Sales	14,035	12,541	9,984	
Other Income	20	47	(101)	
Total Income	14,058	12,591	9,886	
Expenditure				
(Increase)/Decrease - Stock in trade	4,052	(2,145)	242	Reversal in inventory partly due to liquidation of
Consumption of Raw materials	5,253	9,853	5,225	unsold inventory accumulated in previous quarters
Purchase of traded goods	127	-	11	
Staff Cost	3,020	2,682	2,232	
Other Expenditure	1,509	1,504	1,154	
Interest	136	102	15	
Depreciation,amortisation and impairment	458	459	256	
Total Expenditure	14,559	12,459	9,137	
Profit before Tax	(501)	132	749	
Provision for Taxation	11	72	196	
Net Profit After Tax	(512)	60	553	
Operating EBITDA margin	0.5%	5.1%	11.2%	Margins remain under pressure
Tax rate	-2.1%	54.5%	26.2%	·
International sales growth	40.6%	31.6%	-2.4%	
RM cost to sales	67.2%	61.5%	54.9%	Sharp increase in RM/sales
Staff cost to sales	21.5%	21.4%	22.4%	

Source: Company data, Nomura research

# What do the results imply for our earnings estimates for FY12F and ahead?

We are cutting our estimates by 30-45% over FY12-14F, led by lower-than-earlier expected revenue growth and margins.

Changes to our earnings estimates are driven by:

- 1) Slower growth assumptions for the international business and the domestic consumer business for FY13F.
- 2) Our revenue growth assumption estimate for FY12F is 11% y-y, which is at the middle of the guidance of 10-12%, primarily driven by our increased skepticism


on the international markets. We build in growth of 9% in FY13F revenue estimate.

- 3) Our margin estimate of 7.7% for FY12 is at the lower end of guidance as we think competitive pressure will hamper the recovery. However, margins will improve in FY13 to 9.5%, though still lower than earlier peaks, in our view.
- 4) Our EPS estimate of INR6.51 for FY12F suggests an earnings decline of 55% y-y before it recovers to INR10 in FY13F. We are building in no benefit from increased R&D spending in FY12F.

### What are consensus estimates building in?

Mean consensus EPS estimates have corrected by 45-50% for CRG since their peak, with recent estimates falling even lower. However, FY12 consensus estimates face further downside of 10-15% given risks to margins and sales from a likely severe global slowdown, in our view.

Fig. 7: Further downside of 10-15% possible for FY12F earnings INR



Source: Bloomberg

# Valuation: The stock is still expensive on lowered estimates; downgrade to Reduce

We now value CRG at 11x (from 15x earlier) Sep-13F EPS of INR11.8 to arrive at our revised TP of INR130 (from INR240). Our change in multiple from 15x to 11x reflects a discount to the mid-cycle multiples as the uncertainty over earnings for CRG has increased substantially and its ROE profile continues to deteriorate.

We peg CRG's target multiple at a 10% discount to the peer average of 12.3x Sep-13F EPS. Our assigned discount of 10% to the sector average is justified as CRG's ROE profile is expected to remain at a 15-20% discount to the peers given the structural shift in margins and rising risks in international markets.

### Fig. 8: Stock is trading at 10-year mean trading multiples...

Fig. 9: ...while slightly lower on average levels since FY06 Crompton Greaves 1-year fwd P/E Crompton Greaves 1-year fwd P/B





Source: Company, Bloomberg, Nomura research

Source: Company, Bloomberg, Nomura research

Fig. 10: Sector valuation comps INR

			Target	Market		P/E (x)		EPS C	AGR		ROE	(%)		
	Ticker	Rating	Price	Price	FY11	FY12F	FY13F	FY14F	FY10-12F	FY12-14F	FY11	FY12F	FY13F	FY14F
BHEL	BHEL IN	Buy	332	260	11.9	9.6	9.2	9.2	11%	2%	33.3	29.5	25.5	21.7
ABB India	ABB IN	Reduce	525	863	130.8	58.8	39.7	31.3	-6%	37%	2.6	12.1	15.9	17.5
Cummins India	KKC IN	Reduce	375	422	20.2	20.9	18.3	15.5	13%	16%	35.1	31.2	29.2	30.3
Crompton Greaves	CRG IN	Reduce	130	143	9.9	22.0	14.3	10.4	-29%	45%	32.1	12.1	16.6	19.6
Thermax	TMX IN	Reduce	440	487	15.2	14.8	17.3	14.0	23%	3%	31.9	27.0	19.5	21.0
Larsen & Toubro	LT IN	Buy	1691	1,355	15.2	13.0	11.0	9.4	17%	18%	19.7	18.3	18.6	18.5
Voltas	VOLT IN	Buy	150	100	10.4	12.2	10.2	8.3	-16%	21%	29.2	21.7	18.4	19.5
Covered companies' average	е				13.8	15.4	13.4	11.1	3%	17%	30.2	23.3	21.3	21.8
Siemens India*	SIEM IN	Unrated	-	777	30.1	29.9	28.7	24.8	8%	10%	25.5	22.8	20.3	20.6
Areva T&D India*	ATD IN	Unrated	-	177	24.4	21.8	17.8	14.2	1%	24%	18.0	17.4	18.5	20.8
AIA Engineering*	AIAE IN	Unrated	-	308	15.9	16.3	13.6	11.7	2%	18%	18.6	15.7	16.3	16.5
Bharat Electronics*	BHE IN	Unrated	-	1,482	14.8	13.0	11.3	10.2	11%	12%	16.8	16.9	16.4	16.5
Carborundum Universal*	CU IN	Unrated	-	154	8.4	7.9	6.7	10.9	34%	-15%	22.4	21.2	21.4	21.6
Blue Star*	BLSTR IN	Unrated	-	179	10.0	10.2	7.9	7.2	-6%	19%	27.0	25.0	29.1	32.5
Sector Average					15.1	15.6	12.5	11.0	6%	15%	24.7	20.5	20.2	21.7

Price as on 7th February, 2012.

Source: Company data, Bloomberg, Nomura estimates

### Investment risks

- -A significant movement in currency.
- -A pick-up in the domestic power sector's investments.
- -Recovery from industrial slowdown could boost the industrial segment.
- -Increased consumer spending could help fans and lighting segments performance.

<sup>\*</sup> Consensus estimates for unrated companies

### **Appendix A-1**

### **Analyst Certification**

We, Amar Kedia and Indrajit Yadav, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

## **Issuer Specific Regulatory Disclosures Mentioned companies**

Issuer name	Ticker	Price	Price date	Stock rating	Sector rating	Disclosures
Crompton Greaves	CRG IN	INR 144	08-Feb-2012	Reduce	Not rated	
Provious Pating						

### Previous Rating

Issuer name	Previous Rating	Date of change
Crompton Greaves	Buy	08-Feb-2012

### **Crompton Greaves (CRG IN)** INR 144 (08-Feb-2012) Reduce (Sector rating: Not rated) Rating and target price chart (three year history) Crompton Greaves Date Rating Target price Closing price As of 07-Feb-2012 28-Jul-11 240.00 172.70 Currency = INR 05-Jul-11 325.00 259.55 550.00 335.00 287.95 07-Apr-11 22-Nov-10 380.00 330.90 500.00 12-Aug-10 335.00 283.15 450.00 10-Mar-10 306.00 244.25 09-Feb-10 Buy 243.11 400.00 09-Feb-10 535.00 243.11 350.00 300.00 250.00 200.00 150.00 100.00 50.00 0.00 2009/07/01 2010/01/01 2010/07/01 2011/01/01 2011/07/01 2012/01/01 Source: Bloomberg, Nomura Research

For explanation of ratings refer to the stock rating keys located after chart(s)

**Valuation Methodology** We value the core business at 11x Sep-13F EPS of INR11.8 to arrive at our target price of INR130. Our multiple of 11x reflects a discount to the mid-cycle multiple for the stock, which we believe is justified under the current circumstance of reduced earnings visibility.

Risks that may impede the achievement of the target price Key upside risks: 1)Significant movement in currency. 2)Pick-up in domestic power sector investments. 3)Recovery from industrial slowdown could boost the industrial segment. 4)Increased consumer spending could help the fans and lighting segments.

### Important Disclosures

### Online availability of research and conflict-of-interest disclosures

Nomura research is available on <a href="www.nomuranow.com">www.nomuranow.com</a>, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at <a href="http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx">http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx</a> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email <a href="mailto:grpsupport-eu@nomura.com">grpsupport-eu@nomura.com</a> for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Industry Specialists identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. Marketing Analysts identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura's Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector.

### Distribution of ratings (US)

The distribution of all ratings published by Nomura US Equity Research is as follows:

35% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 11% of companies with this rating are investment banking clients of the Nomura Group\*.

59% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 2% of companies with this rating are investment banking clients of the Nomura Group\*.

6% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 0% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

### **Distribution of ratings (Global)**

The distribution of all ratings published by Nomura Global Equity Research is as follows:

47% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 40% of companies with this rating are investment banking clients of the Nomura Group\*.

43% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 45% of companies with this rating are investment banking clients of the Nomura Group\*.

10% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 21% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America
The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock.
Analysts may also indicate absolute upside to target price defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

### STOCKS

A rating of 'Buy', indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of 'Neutral', indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of 'Reduce', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of 'Suspended', indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including, but not limited to, when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company. Benchmarks are as follows: United States/Europe: Please see valuation methodologies for explanations of relevant benchmarks for stocks (accessible through the left hand side of the Nomura Disclosure web page: <a href="http://go.nomuranow.com/research/globalresearchportal">http://go.nomuranow.com/research/globalresearchportal</a>); Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

### SECTORS

A 'Bullish' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A 'Bearish' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A 'Bearish' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months.

Benchmarks are as follows: **United States**: S&P 500; **Europe**: Dow Jones STOXX 600; **Global Emerging Markets (ex-Asia)**: MSCI Emerging Markets ex-Asia.

Explanation of Nomura's equity research rating system in Japan and Asia ex-Japan STOCKS

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc.

A 'Buy' recommendation indicates that potential upside is 15% or more. A 'Neutral' recommendation indicates that potential upside is less than 15% or downside is less than 5%. A 'Reduce' recommendation indicates that potential downside is 5% or more. A rating of 'Suspended' indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company.

Securities and/or companies that are labelled as 'Not rated' or shown as 'No rating' are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies.

### **SECTORS**

A 'Bullish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A 'Neutral' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A 'Bearish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

### **Target Price**

A Target Price, if discussed, reflect in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

### **Disclaimers**

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. Affiliates and subsidiaries of Nomura Holdings, Inc. (collectively, the 'Nomura Group'), include: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('Nlplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at http://dis.kofia.or.kr ); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Capital Nomura Securities Public Company Limited ('CNS'), Thailand; Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; Nomura International (Hong Kong) Ltd., Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, INC 23

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information. Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (as defined within Financial Services Authority ('FSA') rules in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance whic

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by NIplc, which is authorized and regulated by the FSA and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are 'eligible counterparties' or 'professional clients' as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution in the Kingdom of Saudi Arabia ('Saudi Arabia') or to clients other than 'professional clients' in the United Arab Emirates ('UAE') by Nomura Saudi Arabia, NIplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person located in Saudi Arabia or to clients other than 'professional clients' in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of Saudi Arabia or the UAE.

NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. Further information on any of the securities mentioned herein may be obtained upon request. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request. Disclosure information is available at the Nomura Disclosure web page; http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx